Research programme: Hsp90 inhibitors - Isomerase Therapeutics

Drug Profile

Research programme: Hsp90 inhibitors - Isomerase Therapeutics

Alternative Names: BC 226; BC 274; BHI-001

Latest Information Update: 08 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotica Technology
  • Class Macrolides
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 08 Aug 2011 Hsp90 inhibitors programme available for partnering/licensing following completion of preclinical proof-of-concept studies.
  • 27 Jan 2011 No development reported - Preclinical for Cancer in United Kingdom (Parenteral)
  • 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top